Research ArticleArticle
Open Access
Effect of Fatigue on Health-Related Quality of Life and Work Productivity in Psoriatic Arthritis: Findings From a Real-World Survey
Laure Gossec, Jessica A. Walsh, Kaleb Michaud, Elizabeth Holdsworth, Steve Peterson, Sophie Meakin, Feifei Yang, Nicola Booth, Soumya D. Chakravarty, James Piercy, Natalie Dennis and Alexis Ogdie
The Journal of Rheumatology July 2022, jrheum.211288; DOI: https://doi.org/10.3899/jrheum.211288
Laure Gossec
LG received research grants from Amgen, Galapagos, Lilly, Pfizer, Sandoz, and Sanofi; and consulting fees from AbbVie, Amgen, BMS, Biogen, Celgene, Galapagos, Gilead, Janssen, Lilly, Novartis, Pfizer, Samsung Bioepis, Sanofi-Aventis, and UCB; all are unrelated to the present study. JAW received grants from AbbVie, Merck, and Pfizer; and consulting fees from AbbVie, Amgen, Janssen, Lilly, Novartis, Pfizer, and UCB; all are unrelated to this work. KM has no competing interest to disclose. SP and FY are employees and shareholders of Janssen Pharmaceuticals, LLC. SDC is an employee of Janssen Scientific Affairs, LLC, and a shareholder in Johnson & Johnson, of which Janssen Scientific Affairs, LLC, is a wholly owned subsidiary. AO has served as a consultant for AbbVie, Amgen, BMS, Celgene, CorEvitas, Gilead, Janssen, Lilly, Novartis, Pfizer, and UCB; and received grant funding to the University of Pennsylvania from AbbVie, Novartis, and Pfizer, and to Forward Databank from Amgen. EH, SM, NB, and JP are employees of Adelphi Real World, who received funding from Janssen for this analysis. Data collection was undertaken by Adelphi Real World as part of an independent survey, entitled the Adelphi SpA IV Disease Specific Programme, sponsored by multiple pharmaceutical companies, one of which was Janssen. Janssen did not influence the original survey through either contribution to the design of record forms or data collection. The analysis described here using data from the Adelphi SpA IV Disease Specific Programme was funded by Janssen. ND declares no conflicts of interest relevant to this article. L. Gossec, MD, PhD, Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, and Pitié-Salpêtrière Hospital, AP-HP, Sorbonne Université, Rheumatology Department, Paris, France; J.A. Walsh, MD, University of Utah and Salt Lake City Veterans Affairs Medical Centers, Salt Lake City, Utah, USA; K. Michaud, PhD, University of Nebraska Medical Center, Omaha, Nebraska, and Forward Databank, Wichita, Kansas, USA; E. Holdsworth, MSc, S. Meakin, BSc, N. Booth, MSc, J. Piercy, MSc, Adelphi Real World, Bollington, Macclesfield, UK; S. Peterson, MS, F. Yang, MD, Janssen Global Services, LLC, Raritan, New Jersey, USA; S.D. Chakravarty, MD, Janssen Scientific Affairs, LLC, Titusville, New Jersey, and Drexel University College of Medicine, Philadelphia, Pennsylvania, USA; N. Dennis, BA, Amaris, Health Economics and Market Access, Paris, France; A. Ogdie, MD, MSCE, Perelman School of Medicine, Philadelphia, Pennsylvania, USA. Address correspondence to Dr. N. Booth, Adelphi Real World, Adelphi Mill, Bollington, Macclesfield, Cheshire, SK10 5JB, UK. Email: nicola.massey@adelphigroup.com. Accepted for publication May 20, 2022.
Jessica A. Walsh
LG received research grants from Amgen, Galapagos, Lilly, Pfizer, Sandoz, and Sanofi; and consulting fees from AbbVie, Amgen, BMS, Biogen, Celgene, Galapagos, Gilead, Janssen, Lilly, Novartis, Pfizer, Samsung Bioepis, Sanofi-Aventis, and UCB; all are unrelated to the present study. JAW received grants from AbbVie, Merck, and Pfizer; and consulting fees from AbbVie, Amgen, Janssen, Lilly, Novartis, Pfizer, and UCB; all are unrelated to this work. KM has no competing interest to disclose. SP and FY are employees and shareholders of Janssen Pharmaceuticals, LLC. SDC is an employee of Janssen Scientific Affairs, LLC, and a shareholder in Johnson & Johnson, of which Janssen Scientific Affairs, LLC, is a wholly owned subsidiary. AO has served as a consultant for AbbVie, Amgen, BMS, Celgene, CorEvitas, Gilead, Janssen, Lilly, Novartis, Pfizer, and UCB; and received grant funding to the University of Pennsylvania from AbbVie, Novartis, and Pfizer, and to Forward Databank from Amgen. EH, SM, NB, and JP are employees of Adelphi Real World, who received funding from Janssen for this analysis. Data collection was undertaken by Adelphi Real World as part of an independent survey, entitled the Adelphi SpA IV Disease Specific Programme, sponsored by multiple pharmaceutical companies, one of which was Janssen. Janssen did not influence the original survey through either contribution to the design of record forms or data collection. The analysis described here using data from the Adelphi SpA IV Disease Specific Programme was funded by Janssen. ND declares no conflicts of interest relevant to this article. L. Gossec, MD, PhD, Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, and Pitié-Salpêtrière Hospital, AP-HP, Sorbonne Université, Rheumatology Department, Paris, France; J.A. Walsh, MD, University of Utah and Salt Lake City Veterans Affairs Medical Centers, Salt Lake City, Utah, USA; K. Michaud, PhD, University of Nebraska Medical Center, Omaha, Nebraska, and Forward Databank, Wichita, Kansas, USA; E. Holdsworth, MSc, S. Meakin, BSc, N. Booth, MSc, J. Piercy, MSc, Adelphi Real World, Bollington, Macclesfield, UK; S. Peterson, MS, F. Yang, MD, Janssen Global Services, LLC, Raritan, New Jersey, USA; S.D. Chakravarty, MD, Janssen Scientific Affairs, LLC, Titusville, New Jersey, and Drexel University College of Medicine, Philadelphia, Pennsylvania, USA; N. Dennis, BA, Amaris, Health Economics and Market Access, Paris, France; A. Ogdie, MD, MSCE, Perelman School of Medicine, Philadelphia, Pennsylvania, USA. Address correspondence to Dr. N. Booth, Adelphi Real World, Adelphi Mill, Bollington, Macclesfield, Cheshire, SK10 5JB, UK. Email: nicola.massey@adelphigroup.com. Accepted for publication May 20, 2022.
Kaleb Michaud
LG received research grants from Amgen, Galapagos, Lilly, Pfizer, Sandoz, and Sanofi; and consulting fees from AbbVie, Amgen, BMS, Biogen, Celgene, Galapagos, Gilead, Janssen, Lilly, Novartis, Pfizer, Samsung Bioepis, Sanofi-Aventis, and UCB; all are unrelated to the present study. JAW received grants from AbbVie, Merck, and Pfizer; and consulting fees from AbbVie, Amgen, Janssen, Lilly, Novartis, Pfizer, and UCB; all are unrelated to this work. KM has no competing interest to disclose. SP and FY are employees and shareholders of Janssen Pharmaceuticals, LLC. SDC is an employee of Janssen Scientific Affairs, LLC, and a shareholder in Johnson & Johnson, of which Janssen Scientific Affairs, LLC, is a wholly owned subsidiary. AO has served as a consultant for AbbVie, Amgen, BMS, Celgene, CorEvitas, Gilead, Janssen, Lilly, Novartis, Pfizer, and UCB; and received grant funding to the University of Pennsylvania from AbbVie, Novartis, and Pfizer, and to Forward Databank from Amgen. EH, SM, NB, and JP are employees of Adelphi Real World, who received funding from Janssen for this analysis. Data collection was undertaken by Adelphi Real World as part of an independent survey, entitled the Adelphi SpA IV Disease Specific Programme, sponsored by multiple pharmaceutical companies, one of which was Janssen. Janssen did not influence the original survey through either contribution to the design of record forms or data collection. The analysis described here using data from the Adelphi SpA IV Disease Specific Programme was funded by Janssen. ND declares no conflicts of interest relevant to this article. L. Gossec, MD, PhD, Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, and Pitié-Salpêtrière Hospital, AP-HP, Sorbonne Université, Rheumatology Department, Paris, France; J.A. Walsh, MD, University of Utah and Salt Lake City Veterans Affairs Medical Centers, Salt Lake City, Utah, USA; K. Michaud, PhD, University of Nebraska Medical Center, Omaha, Nebraska, and Forward Databank, Wichita, Kansas, USA; E. Holdsworth, MSc, S. Meakin, BSc, N. Booth, MSc, J. Piercy, MSc, Adelphi Real World, Bollington, Macclesfield, UK; S. Peterson, MS, F. Yang, MD, Janssen Global Services, LLC, Raritan, New Jersey, USA; S.D. Chakravarty, MD, Janssen Scientific Affairs, LLC, Titusville, New Jersey, and Drexel University College of Medicine, Philadelphia, Pennsylvania, USA; N. Dennis, BA, Amaris, Health Economics and Market Access, Paris, France; A. Ogdie, MD, MSCE, Perelman School of Medicine, Philadelphia, Pennsylvania, USA. Address correspondence to Dr. N. Booth, Adelphi Real World, Adelphi Mill, Bollington, Macclesfield, Cheshire, SK10 5JB, UK. Email: nicola.massey@adelphigroup.com. Accepted for publication May 20, 2022.
Elizabeth Holdsworth
LG received research grants from Amgen, Galapagos, Lilly, Pfizer, Sandoz, and Sanofi; and consulting fees from AbbVie, Amgen, BMS, Biogen, Celgene, Galapagos, Gilead, Janssen, Lilly, Novartis, Pfizer, Samsung Bioepis, Sanofi-Aventis, and UCB; all are unrelated to the present study. JAW received grants from AbbVie, Merck, and Pfizer; and consulting fees from AbbVie, Amgen, Janssen, Lilly, Novartis, Pfizer, and UCB; all are unrelated to this work. KM has no competing interest to disclose. SP and FY are employees and shareholders of Janssen Pharmaceuticals, LLC. SDC is an employee of Janssen Scientific Affairs, LLC, and a shareholder in Johnson & Johnson, of which Janssen Scientific Affairs, LLC, is a wholly owned subsidiary. AO has served as a consultant for AbbVie, Amgen, BMS, Celgene, CorEvitas, Gilead, Janssen, Lilly, Novartis, Pfizer, and UCB; and received grant funding to the University of Pennsylvania from AbbVie, Novartis, and Pfizer, and to Forward Databank from Amgen. EH, SM, NB, and JP are employees of Adelphi Real World, who received funding from Janssen for this analysis. Data collection was undertaken by Adelphi Real World as part of an independent survey, entitled the Adelphi SpA IV Disease Specific Programme, sponsored by multiple pharmaceutical companies, one of which was Janssen. Janssen did not influence the original survey through either contribution to the design of record forms or data collection. The analysis described here using data from the Adelphi SpA IV Disease Specific Programme was funded by Janssen. ND declares no conflicts of interest relevant to this article. L. Gossec, MD, PhD, Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, and Pitié-Salpêtrière Hospital, AP-HP, Sorbonne Université, Rheumatology Department, Paris, France; J.A. Walsh, MD, University of Utah and Salt Lake City Veterans Affairs Medical Centers, Salt Lake City, Utah, USA; K. Michaud, PhD, University of Nebraska Medical Center, Omaha, Nebraska, and Forward Databank, Wichita, Kansas, USA; E. Holdsworth, MSc, S. Meakin, BSc, N. Booth, MSc, J. Piercy, MSc, Adelphi Real World, Bollington, Macclesfield, UK; S. Peterson, MS, F. Yang, MD, Janssen Global Services, LLC, Raritan, New Jersey, USA; S.D. Chakravarty, MD, Janssen Scientific Affairs, LLC, Titusville, New Jersey, and Drexel University College of Medicine, Philadelphia, Pennsylvania, USA; N. Dennis, BA, Amaris, Health Economics and Market Access, Paris, France; A. Ogdie, MD, MSCE, Perelman School of Medicine, Philadelphia, Pennsylvania, USA. Address correspondence to Dr. N. Booth, Adelphi Real World, Adelphi Mill, Bollington, Macclesfield, Cheshire, SK10 5JB, UK. Email: nicola.massey@adelphigroup.com. Accepted for publication May 20, 2022.
Steve Peterson
LG received research grants from Amgen, Galapagos, Lilly, Pfizer, Sandoz, and Sanofi; and consulting fees from AbbVie, Amgen, BMS, Biogen, Celgene, Galapagos, Gilead, Janssen, Lilly, Novartis, Pfizer, Samsung Bioepis, Sanofi-Aventis, and UCB; all are unrelated to the present study. JAW received grants from AbbVie, Merck, and Pfizer; and consulting fees from AbbVie, Amgen, Janssen, Lilly, Novartis, Pfizer, and UCB; all are unrelated to this work. KM has no competing interest to disclose. SP and FY are employees and shareholders of Janssen Pharmaceuticals, LLC. SDC is an employee of Janssen Scientific Affairs, LLC, and a shareholder in Johnson & Johnson, of which Janssen Scientific Affairs, LLC, is a wholly owned subsidiary. AO has served as a consultant for AbbVie, Amgen, BMS, Celgene, CorEvitas, Gilead, Janssen, Lilly, Novartis, Pfizer, and UCB; and received grant funding to the University of Pennsylvania from AbbVie, Novartis, and Pfizer, and to Forward Databank from Amgen. EH, SM, NB, and JP are employees of Adelphi Real World, who received funding from Janssen for this analysis. Data collection was undertaken by Adelphi Real World as part of an independent survey, entitled the Adelphi SpA IV Disease Specific Programme, sponsored by multiple pharmaceutical companies, one of which was Janssen. Janssen did not influence the original survey through either contribution to the design of record forms or data collection. The analysis described here using data from the Adelphi SpA IV Disease Specific Programme was funded by Janssen. ND declares no conflicts of interest relevant to this article. L. Gossec, MD, PhD, Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, and Pitié-Salpêtrière Hospital, AP-HP, Sorbonne Université, Rheumatology Department, Paris, France; J.A. Walsh, MD, University of Utah and Salt Lake City Veterans Affairs Medical Centers, Salt Lake City, Utah, USA; K. Michaud, PhD, University of Nebraska Medical Center, Omaha, Nebraska, and Forward Databank, Wichita, Kansas, USA; E. Holdsworth, MSc, S. Meakin, BSc, N. Booth, MSc, J. Piercy, MSc, Adelphi Real World, Bollington, Macclesfield, UK; S. Peterson, MS, F. Yang, MD, Janssen Global Services, LLC, Raritan, New Jersey, USA; S.D. Chakravarty, MD, Janssen Scientific Affairs, LLC, Titusville, New Jersey, and Drexel University College of Medicine, Philadelphia, Pennsylvania, USA; N. Dennis, BA, Amaris, Health Economics and Market Access, Paris, France; A. Ogdie, MD, MSCE, Perelman School of Medicine, Philadelphia, Pennsylvania, USA. Address correspondence to Dr. N. Booth, Adelphi Real World, Adelphi Mill, Bollington, Macclesfield, Cheshire, SK10 5JB, UK. Email: nicola.massey@adelphigroup.com. Accepted for publication May 20, 2022.
Sophie Meakin
LG received research grants from Amgen, Galapagos, Lilly, Pfizer, Sandoz, and Sanofi; and consulting fees from AbbVie, Amgen, BMS, Biogen, Celgene, Galapagos, Gilead, Janssen, Lilly, Novartis, Pfizer, Samsung Bioepis, Sanofi-Aventis, and UCB; all are unrelated to the present study. JAW received grants from AbbVie, Merck, and Pfizer; and consulting fees from AbbVie, Amgen, Janssen, Lilly, Novartis, Pfizer, and UCB; all are unrelated to this work. KM has no competing interest to disclose. SP and FY are employees and shareholders of Janssen Pharmaceuticals, LLC. SDC is an employee of Janssen Scientific Affairs, LLC, and a shareholder in Johnson & Johnson, of which Janssen Scientific Affairs, LLC, is a wholly owned subsidiary. AO has served as a consultant for AbbVie, Amgen, BMS, Celgene, CorEvitas, Gilead, Janssen, Lilly, Novartis, Pfizer, and UCB; and received grant funding to the University of Pennsylvania from AbbVie, Novartis, and Pfizer, and to Forward Databank from Amgen. EH, SM, NB, and JP are employees of Adelphi Real World, who received funding from Janssen for this analysis. Data collection was undertaken by Adelphi Real World as part of an independent survey, entitled the Adelphi SpA IV Disease Specific Programme, sponsored by multiple pharmaceutical companies, one of which was Janssen. Janssen did not influence the original survey through either contribution to the design of record forms or data collection. The analysis described here using data from the Adelphi SpA IV Disease Specific Programme was funded by Janssen. ND declares no conflicts of interest relevant to this article. L. Gossec, MD, PhD, Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, and Pitié-Salpêtrière Hospital, AP-HP, Sorbonne Université, Rheumatology Department, Paris, France; J.A. Walsh, MD, University of Utah and Salt Lake City Veterans Affairs Medical Centers, Salt Lake City, Utah, USA; K. Michaud, PhD, University of Nebraska Medical Center, Omaha, Nebraska, and Forward Databank, Wichita, Kansas, USA; E. Holdsworth, MSc, S. Meakin, BSc, N. Booth, MSc, J. Piercy, MSc, Adelphi Real World, Bollington, Macclesfield, UK; S. Peterson, MS, F. Yang, MD, Janssen Global Services, LLC, Raritan, New Jersey, USA; S.D. Chakravarty, MD, Janssen Scientific Affairs, LLC, Titusville, New Jersey, and Drexel University College of Medicine, Philadelphia, Pennsylvania, USA; N. Dennis, BA, Amaris, Health Economics and Market Access, Paris, France; A. Ogdie, MD, MSCE, Perelman School of Medicine, Philadelphia, Pennsylvania, USA. Address correspondence to Dr. N. Booth, Adelphi Real World, Adelphi Mill, Bollington, Macclesfield, Cheshire, SK10 5JB, UK. Email: nicola.massey@adelphigroup.com. Accepted for publication May 20, 2022.
Feifei Yang
LG received research grants from Amgen, Galapagos, Lilly, Pfizer, Sandoz, and Sanofi; and consulting fees from AbbVie, Amgen, BMS, Biogen, Celgene, Galapagos, Gilead, Janssen, Lilly, Novartis, Pfizer, Samsung Bioepis, Sanofi-Aventis, and UCB; all are unrelated to the present study. JAW received grants from AbbVie, Merck, and Pfizer; and consulting fees from AbbVie, Amgen, Janssen, Lilly, Novartis, Pfizer, and UCB; all are unrelated to this work. KM has no competing interest to disclose. SP and FY are employees and shareholders of Janssen Pharmaceuticals, LLC. SDC is an employee of Janssen Scientific Affairs, LLC, and a shareholder in Johnson & Johnson, of which Janssen Scientific Affairs, LLC, is a wholly owned subsidiary. AO has served as a consultant for AbbVie, Amgen, BMS, Celgene, CorEvitas, Gilead, Janssen, Lilly, Novartis, Pfizer, and UCB; and received grant funding to the University of Pennsylvania from AbbVie, Novartis, and Pfizer, and to Forward Databank from Amgen. EH, SM, NB, and JP are employees of Adelphi Real World, who received funding from Janssen for this analysis. Data collection was undertaken by Adelphi Real World as part of an independent survey, entitled the Adelphi SpA IV Disease Specific Programme, sponsored by multiple pharmaceutical companies, one of which was Janssen. Janssen did not influence the original survey through either contribution to the design of record forms or data collection. The analysis described here using data from the Adelphi SpA IV Disease Specific Programme was funded by Janssen. ND declares no conflicts of interest relevant to this article. L. Gossec, MD, PhD, Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, and Pitié-Salpêtrière Hospital, AP-HP, Sorbonne Université, Rheumatology Department, Paris, France; J.A. Walsh, MD, University of Utah and Salt Lake City Veterans Affairs Medical Centers, Salt Lake City, Utah, USA; K. Michaud, PhD, University of Nebraska Medical Center, Omaha, Nebraska, and Forward Databank, Wichita, Kansas, USA; E. Holdsworth, MSc, S. Meakin, BSc, N. Booth, MSc, J. Piercy, MSc, Adelphi Real World, Bollington, Macclesfield, UK; S. Peterson, MS, F. Yang, MD, Janssen Global Services, LLC, Raritan, New Jersey, USA; S.D. Chakravarty, MD, Janssen Scientific Affairs, LLC, Titusville, New Jersey, and Drexel University College of Medicine, Philadelphia, Pennsylvania, USA; N. Dennis, BA, Amaris, Health Economics and Market Access, Paris, France; A. Ogdie, MD, MSCE, Perelman School of Medicine, Philadelphia, Pennsylvania, USA. Address correspondence to Dr. N. Booth, Adelphi Real World, Adelphi Mill, Bollington, Macclesfield, Cheshire, SK10 5JB, UK. Email: nicola.massey@adelphigroup.com. Accepted for publication May 20, 2022.
Nicola Booth
LG received research grants from Amgen, Galapagos, Lilly, Pfizer, Sandoz, and Sanofi; and consulting fees from AbbVie, Amgen, BMS, Biogen, Celgene, Galapagos, Gilead, Janssen, Lilly, Novartis, Pfizer, Samsung Bioepis, Sanofi-Aventis, and UCB; all are unrelated to the present study. JAW received grants from AbbVie, Merck, and Pfizer; and consulting fees from AbbVie, Amgen, Janssen, Lilly, Novartis, Pfizer, and UCB; all are unrelated to this work. KM has no competing interest to disclose. SP and FY are employees and shareholders of Janssen Pharmaceuticals, LLC. SDC is an employee of Janssen Scientific Affairs, LLC, and a shareholder in Johnson & Johnson, of which Janssen Scientific Affairs, LLC, is a wholly owned subsidiary. AO has served as a consultant for AbbVie, Amgen, BMS, Celgene, CorEvitas, Gilead, Janssen, Lilly, Novartis, Pfizer, and UCB; and received grant funding to the University of Pennsylvania from AbbVie, Novartis, and Pfizer, and to Forward Databank from Amgen. EH, SM, NB, and JP are employees of Adelphi Real World, who received funding from Janssen for this analysis. Data collection was undertaken by Adelphi Real World as part of an independent survey, entitled the Adelphi SpA IV Disease Specific Programme, sponsored by multiple pharmaceutical companies, one of which was Janssen. Janssen did not influence the original survey through either contribution to the design of record forms or data collection. The analysis described here using data from the Adelphi SpA IV Disease Specific Programme was funded by Janssen. ND declares no conflicts of interest relevant to this article. L. Gossec, MD, PhD, Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, and Pitié-Salpêtrière Hospital, AP-HP, Sorbonne Université, Rheumatology Department, Paris, France; J.A. Walsh, MD, University of Utah and Salt Lake City Veterans Affairs Medical Centers, Salt Lake City, Utah, USA; K. Michaud, PhD, University of Nebraska Medical Center, Omaha, Nebraska, and Forward Databank, Wichita, Kansas, USA; E. Holdsworth, MSc, S. Meakin, BSc, N. Booth, MSc, J. Piercy, MSc, Adelphi Real World, Bollington, Macclesfield, UK; S. Peterson, MS, F. Yang, MD, Janssen Global Services, LLC, Raritan, New Jersey, USA; S.D. Chakravarty, MD, Janssen Scientific Affairs, LLC, Titusville, New Jersey, and Drexel University College of Medicine, Philadelphia, Pennsylvania, USA; N. Dennis, BA, Amaris, Health Economics and Market Access, Paris, France; A. Ogdie, MD, MSCE, Perelman School of Medicine, Philadelphia, Pennsylvania, USA. Address correspondence to Dr. N. Booth, Adelphi Real World, Adelphi Mill, Bollington, Macclesfield, Cheshire, SK10 5JB, UK. Email: nicola.massey@adelphigroup.com. Accepted for publication May 20, 2022.
Soumya D. Chakravarty
LG received research grants from Amgen, Galapagos, Lilly, Pfizer, Sandoz, and Sanofi; and consulting fees from AbbVie, Amgen, BMS, Biogen, Celgene, Galapagos, Gilead, Janssen, Lilly, Novartis, Pfizer, Samsung Bioepis, Sanofi-Aventis, and UCB; all are unrelated to the present study. JAW received grants from AbbVie, Merck, and Pfizer; and consulting fees from AbbVie, Amgen, Janssen, Lilly, Novartis, Pfizer, and UCB; all are unrelated to this work. KM has no competing interest to disclose. SP and FY are employees and shareholders of Janssen Pharmaceuticals, LLC. SDC is an employee of Janssen Scientific Affairs, LLC, and a shareholder in Johnson & Johnson, of which Janssen Scientific Affairs, LLC, is a wholly owned subsidiary. AO has served as a consultant for AbbVie, Amgen, BMS, Celgene, CorEvitas, Gilead, Janssen, Lilly, Novartis, Pfizer, and UCB; and received grant funding to the University of Pennsylvania from AbbVie, Novartis, and Pfizer, and to Forward Databank from Amgen. EH, SM, NB, and JP are employees of Adelphi Real World, who received funding from Janssen for this analysis. Data collection was undertaken by Adelphi Real World as part of an independent survey, entitled the Adelphi SpA IV Disease Specific Programme, sponsored by multiple pharmaceutical companies, one of which was Janssen. Janssen did not influence the original survey through either contribution to the design of record forms or data collection. The analysis described here using data from the Adelphi SpA IV Disease Specific Programme was funded by Janssen. ND declares no conflicts of interest relevant to this article. L. Gossec, MD, PhD, Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, and Pitié-Salpêtrière Hospital, AP-HP, Sorbonne Université, Rheumatology Department, Paris, France; J.A. Walsh, MD, University of Utah and Salt Lake City Veterans Affairs Medical Centers, Salt Lake City, Utah, USA; K. Michaud, PhD, University of Nebraska Medical Center, Omaha, Nebraska, and Forward Databank, Wichita, Kansas, USA; E. Holdsworth, MSc, S. Meakin, BSc, N. Booth, MSc, J. Piercy, MSc, Adelphi Real World, Bollington, Macclesfield, UK; S. Peterson, MS, F. Yang, MD, Janssen Global Services, LLC, Raritan, New Jersey, USA; S.D. Chakravarty, MD, Janssen Scientific Affairs, LLC, Titusville, New Jersey, and Drexel University College of Medicine, Philadelphia, Pennsylvania, USA; N. Dennis, BA, Amaris, Health Economics and Market Access, Paris, France; A. Ogdie, MD, MSCE, Perelman School of Medicine, Philadelphia, Pennsylvania, USA. Address correspondence to Dr. N. Booth, Adelphi Real World, Adelphi Mill, Bollington, Macclesfield, Cheshire, SK10 5JB, UK. Email: nicola.massey@adelphigroup.com. Accepted for publication May 20, 2022.
James Piercy
LG received research grants from Amgen, Galapagos, Lilly, Pfizer, Sandoz, and Sanofi; and consulting fees from AbbVie, Amgen, BMS, Biogen, Celgene, Galapagos, Gilead, Janssen, Lilly, Novartis, Pfizer, Samsung Bioepis, Sanofi-Aventis, and UCB; all are unrelated to the present study. JAW received grants from AbbVie, Merck, and Pfizer; and consulting fees from AbbVie, Amgen, Janssen, Lilly, Novartis, Pfizer, and UCB; all are unrelated to this work. KM has no competing interest to disclose. SP and FY are employees and shareholders of Janssen Pharmaceuticals, LLC. SDC is an employee of Janssen Scientific Affairs, LLC, and a shareholder in Johnson & Johnson, of which Janssen Scientific Affairs, LLC, is a wholly owned subsidiary. AO has served as a consultant for AbbVie, Amgen, BMS, Celgene, CorEvitas, Gilead, Janssen, Lilly, Novartis, Pfizer, and UCB; and received grant funding to the University of Pennsylvania from AbbVie, Novartis, and Pfizer, and to Forward Databank from Amgen. EH, SM, NB, and JP are employees of Adelphi Real World, who received funding from Janssen for this analysis. Data collection was undertaken by Adelphi Real World as part of an independent survey, entitled the Adelphi SpA IV Disease Specific Programme, sponsored by multiple pharmaceutical companies, one of which was Janssen. Janssen did not influence the original survey through either contribution to the design of record forms or data collection. The analysis described here using data from the Adelphi SpA IV Disease Specific Programme was funded by Janssen. ND declares no conflicts of interest relevant to this article. L. Gossec, MD, PhD, Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, and Pitié-Salpêtrière Hospital, AP-HP, Sorbonne Université, Rheumatology Department, Paris, France; J.A. Walsh, MD, University of Utah and Salt Lake City Veterans Affairs Medical Centers, Salt Lake City, Utah, USA; K. Michaud, PhD, University of Nebraska Medical Center, Omaha, Nebraska, and Forward Databank, Wichita, Kansas, USA; E. Holdsworth, MSc, S. Meakin, BSc, N. Booth, MSc, J. Piercy, MSc, Adelphi Real World, Bollington, Macclesfield, UK; S. Peterson, MS, F. Yang, MD, Janssen Global Services, LLC, Raritan, New Jersey, USA; S.D. Chakravarty, MD, Janssen Scientific Affairs, LLC, Titusville, New Jersey, and Drexel University College of Medicine, Philadelphia, Pennsylvania, USA; N. Dennis, BA, Amaris, Health Economics and Market Access, Paris, France; A. Ogdie, MD, MSCE, Perelman School of Medicine, Philadelphia, Pennsylvania, USA. Address correspondence to Dr. N. Booth, Adelphi Real World, Adelphi Mill, Bollington, Macclesfield, Cheshire, SK10 5JB, UK. Email: nicola.massey@adelphigroup.com. Accepted for publication May 20, 2022.
Natalie Dennis
LG received research grants from Amgen, Galapagos, Lilly, Pfizer, Sandoz, and Sanofi; and consulting fees from AbbVie, Amgen, BMS, Biogen, Celgene, Galapagos, Gilead, Janssen, Lilly, Novartis, Pfizer, Samsung Bioepis, Sanofi-Aventis, and UCB; all are unrelated to the present study. JAW received grants from AbbVie, Merck, and Pfizer; and consulting fees from AbbVie, Amgen, Janssen, Lilly, Novartis, Pfizer, and UCB; all are unrelated to this work. KM has no competing interest to disclose. SP and FY are employees and shareholders of Janssen Pharmaceuticals, LLC. SDC is an employee of Janssen Scientific Affairs, LLC, and a shareholder in Johnson & Johnson, of which Janssen Scientific Affairs, LLC, is a wholly owned subsidiary. AO has served as a consultant for AbbVie, Amgen, BMS, Celgene, CorEvitas, Gilead, Janssen, Lilly, Novartis, Pfizer, and UCB; and received grant funding to the University of Pennsylvania from AbbVie, Novartis, and Pfizer, and to Forward Databank from Amgen. EH, SM, NB, and JP are employees of Adelphi Real World, who received funding from Janssen for this analysis. Data collection was undertaken by Adelphi Real World as part of an independent survey, entitled the Adelphi SpA IV Disease Specific Programme, sponsored by multiple pharmaceutical companies, one of which was Janssen. Janssen did not influence the original survey through either contribution to the design of record forms or data collection. The analysis described here using data from the Adelphi SpA IV Disease Specific Programme was funded by Janssen. ND declares no conflicts of interest relevant to this article. L. Gossec, MD, PhD, Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, and Pitié-Salpêtrière Hospital, AP-HP, Sorbonne Université, Rheumatology Department, Paris, France; J.A. Walsh, MD, University of Utah and Salt Lake City Veterans Affairs Medical Centers, Salt Lake City, Utah, USA; K. Michaud, PhD, University of Nebraska Medical Center, Omaha, Nebraska, and Forward Databank, Wichita, Kansas, USA; E. Holdsworth, MSc, S. Meakin, BSc, N. Booth, MSc, J. Piercy, MSc, Adelphi Real World, Bollington, Macclesfield, UK; S. Peterson, MS, F. Yang, MD, Janssen Global Services, LLC, Raritan, New Jersey, USA; S.D. Chakravarty, MD, Janssen Scientific Affairs, LLC, Titusville, New Jersey, and Drexel University College of Medicine, Philadelphia, Pennsylvania, USA; N. Dennis, BA, Amaris, Health Economics and Market Access, Paris, France; A. Ogdie, MD, MSCE, Perelman School of Medicine, Philadelphia, Pennsylvania, USA. Address correspondence to Dr. N. Booth, Adelphi Real World, Adelphi Mill, Bollington, Macclesfield, Cheshire, SK10 5JB, UK. Email: nicola.massey@adelphigroup.com. Accepted for publication May 20, 2022.
Alexis Ogdie
LG received research grants from Amgen, Galapagos, Lilly, Pfizer, Sandoz, and Sanofi; and consulting fees from AbbVie, Amgen, BMS, Biogen, Celgene, Galapagos, Gilead, Janssen, Lilly, Novartis, Pfizer, Samsung Bioepis, Sanofi-Aventis, and UCB; all are unrelated to the present study. JAW received grants from AbbVie, Merck, and Pfizer; and consulting fees from AbbVie, Amgen, Janssen, Lilly, Novartis, Pfizer, and UCB; all are unrelated to this work. KM has no competing interest to disclose. SP and FY are employees and shareholders of Janssen Pharmaceuticals, LLC. SDC is an employee of Janssen Scientific Affairs, LLC, and a shareholder in Johnson & Johnson, of which Janssen Scientific Affairs, LLC, is a wholly owned subsidiary. AO has served as a consultant for AbbVie, Amgen, BMS, Celgene, CorEvitas, Gilead, Janssen, Lilly, Novartis, Pfizer, and UCB; and received grant funding to the University of Pennsylvania from AbbVie, Novartis, and Pfizer, and to Forward Databank from Amgen. EH, SM, NB, and JP are employees of Adelphi Real World, who received funding from Janssen for this analysis. Data collection was undertaken by Adelphi Real World as part of an independent survey, entitled the Adelphi SpA IV Disease Specific Programme, sponsored by multiple pharmaceutical companies, one of which was Janssen. Janssen did not influence the original survey through either contribution to the design of record forms or data collection. The analysis described here using data from the Adelphi SpA IV Disease Specific Programme was funded by Janssen. ND declares no conflicts of interest relevant to this article. L. Gossec, MD, PhD, Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, and Pitié-Salpêtrière Hospital, AP-HP, Sorbonne Université, Rheumatology Department, Paris, France; J.A. Walsh, MD, University of Utah and Salt Lake City Veterans Affairs Medical Centers, Salt Lake City, Utah, USA; K. Michaud, PhD, University of Nebraska Medical Center, Omaha, Nebraska, and Forward Databank, Wichita, Kansas, USA; E. Holdsworth, MSc, S. Meakin, BSc, N. Booth, MSc, J. Piercy, MSc, Adelphi Real World, Bollington, Macclesfield, UK; S. Peterson, MS, F. Yang, MD, Janssen Global Services, LLC, Raritan, New Jersey, USA; S.D. Chakravarty, MD, Janssen Scientific Affairs, LLC, Titusville, New Jersey, and Drexel University College of Medicine, Philadelphia, Pennsylvania, USA; N. Dennis, BA, Amaris, Health Economics and Market Access, Paris, France; A. Ogdie, MD, MSCE, Perelman School of Medicine, Philadelphia, Pennsylvania, USA. Address correspondence to Dr. N. Booth, Adelphi Real World, Adelphi Mill, Bollington, Macclesfield, Cheshire, SK10 5JB, UK. Email: nicola.massey@adelphigroup.com. Accepted for publication May 20, 2022.
Article Information
jrheum.211288
PubMed
Published By
Print ISSN
Online ISSN
History
- Published online September 15, 2022.
Article Versions
- Latest version (July 15, 2022 - 04:00).
- Latest version (July 29, 2022 - 11:15).
- You are currently viewing a Latest version of this article (September 15, 2022 - 04:00).
- View the most recent version of this article
Copyright & Usage
© 2022 The Journal of Rheumatology
Author Information
- Laure Gossec,
- Jessica A. Walsh,
- Kaleb Michaud,
- Elizabeth Holdsworth,
- Steve Peterson,
- Sophie Meakin,
- Feifei Yang,
- Nicola Booth,
- Soumya D. Chakravarty,
- James Piercy,
- Natalie Dennis and
- Alexis Ogdie
- LG received research grants from Amgen, Galapagos, Lilly, Pfizer, Sandoz, and Sanofi; and consulting fees from AbbVie, Amgen, BMS, Biogen, Celgene, Galapagos, Gilead, Janssen, Lilly, Novartis, Pfizer, Samsung Bioepis, Sanofi-Aventis, and UCB; all are unrelated to the present study. JAW received grants from AbbVie, Merck, and Pfizer; and consulting fees from AbbVie, Amgen, Janssen, Lilly, Novartis, Pfizer, and UCB; all are unrelated to this work. KM has no competing interest to disclose. SP and FY are employees and shareholders of Janssen Pharmaceuticals, LLC. SDC is an employee of Janssen Scientific Affairs, LLC, and a shareholder in Johnson & Johnson, of which Janssen Scientific Affairs, LLC, is a wholly owned subsidiary. AO has served as a consultant for AbbVie, Amgen, BMS, Celgene, CorEvitas, Gilead, Janssen, Lilly, Novartis, Pfizer, and UCB; and received grant funding to the University of Pennsylvania from AbbVie, Novartis, and Pfizer, and to Forward Databank from Amgen. EH, SM, NB, and JP are employees of Adelphi Real World, who received funding from Janssen for this analysis. Data collection was undertaken by Adelphi Real World as part of an independent survey, entitled the Adelphi SpA IV Disease Specific Programme, sponsored by multiple pharmaceutical companies, one of which was Janssen. Janssen did not influence the original survey through either contribution to the design of record forms or data collection. The analysis described here using data from the Adelphi SpA IV Disease Specific Programme was funded by Janssen. ND declares no conflicts of interest relevant to this article.
L. Gossec, MD, PhD, Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, and Pitié-Salpêtrière Hospital, AP-HP, Sorbonne Université, Rheumatology Department, Paris, France; J.A. Walsh, MD, University of Utah and Salt Lake City Veterans Affairs Medical Centers, Salt Lake City, Utah, USA; K. Michaud, PhD, University of Nebraska Medical Center, Omaha, Nebraska, and Forward Databank, Wichita, Kansas, USA; E. Holdsworth, MSc, S. Meakin, BSc, N. Booth, MSc, J. Piercy, MSc, Adelphi Real World, Bollington, Macclesfield, UK; S. Peterson, MS, F. Yang, MD, Janssen Global Services, LLC, Raritan, New Jersey, USA; S.D. Chakravarty, MD, Janssen Scientific Affairs, LLC, Titusville, New Jersey, and Drexel University College of Medicine, Philadelphia, Pennsylvania, USA; N. Dennis, BA, Amaris, Health Economics and Market Access, Paris, France; A. Ogdie, MD, MSCE, Perelman School of Medicine, Philadelphia, Pennsylvania, USA.
Address correspondence to Dr. N. Booth, Adelphi Real World, Adelphi Mill, Bollington, Macclesfield, Cheshire, SK10 5JB, UK. Email: nicola.massey@adelphigroup.com.
Accepted for publication May 20, 2022.
Article usage
Statistics from Altmetric.com
In this issue
The Journal of Rheumatology
Vol. 51, Issue 4
1 Apr 2024
Effect of Fatigue on Health-Related Quality of Life and Work Productivity in Psoriatic Arthritis: Findings From a Real-World Survey
Laure Gossec, Jessica A. Walsh, Kaleb Michaud, Elizabeth Holdsworth, Steve Peterson, Sophie Meakin, Feifei Yang, Nicola Booth, Soumya D. Chakravarty, James Piercy, Natalie Dennis, Alexis Ogdie
The Journal of Rheumatology Jul 2022, jrheum.211288; DOI: 10.3899/jrheum.211288
Effect of Fatigue on Health-Related Quality of Life and Work Productivity in Psoriatic Arthritis: Findings From a Real-World Survey
Laure Gossec, Jessica A. Walsh, Kaleb Michaud, Elizabeth Holdsworth, Steve Peterson, Sophie Meakin, Feifei Yang, Nicola Booth, Soumya D. Chakravarty, James Piercy, Natalie Dennis, Alexis Ogdie
The Journal of Rheumatology Jul 2022, jrheum.211288; DOI: 10.3899/jrheum.211288